Yesterday, Novartis released new data from its head-to-head CLARITY study that shows that its secukinumab (Cosentyx) was significantly more effective than ustekinumab (Stelara) in the treatment of psoriasis in delivering clear or almost clear skin at 12 and 16 weeks.
Yesterday, Novartis released new data from its head-to-head CLARITY study that shows that its secukinumab (Cosentyx) was significantly more effective than ustekinumab (Stelara) in the treatment of psoriasis in delivering clear or almost clear skin at 12 and 16 weeks.
Secukinumab is a targeted biologic therapy that inhibits IL-17A, a cytokine involved in inflammation of entheses.
The results of the CLARITY study show that 66.5% and 72.3% of patients treated with secukinumab (P <.0001) achieved both co-primary endpoints of a response of 90 on the Psoriasis Area and Severity Index (PASI90) and a score of score of 0/1 on the Investigator’s Global Assessment (IGA) (modified 2011), a 5-point tool used to evaluate plaque psoriasis severity, respectively. These results are compared with 47.9% and 55.4%, respectively, of patients treated with ustekinumab achieving PASI90 and IGA 0/1 (P <.0001).
In addition, all key secondary endpoints in the CLARITY study were met, and the safety profile of secukinumab was in line with its known safety profile. The newly released data support findings from the CLEAR study, which found secukinumab to be superior to ustekinumab in achieving sustained skin clearance at 52 weeks.
“These data add to the robust body of evidence supporting the use of Cosentyx to treat moderate to severe plaque psoriasis,” said Mark Lebwohl, MD, chairman of the Waldman department of dermatology at the Icahn School of Medicine at Mount Sinai Hospital in New York. “With these findings clinicians can have even greater confidence including Cosentyx in their treatment plans.”
To date, more than 125,000 patients worldwide have been prescribed secukinumab in the post-marketing setting across all indications. According to Novartis’ third quarter results in 2017, Cosentyx reached $556 million in net sales. Its fourth quarter 2017 results will be announced shortly.
Novartis also recently announced that it is initiating the SURPASS trial; SUPRASS is set to be a head-to-head clinical trial of secukinumab versus a proposed biosimilar adalimumab (referencing Humira and being developed by Sandoz, a Novartis division) in patients with ankylosing spondylitis. Positive results in this trial could potentially make secukinumab a top competitor for an increased share of the market for inflammatory disease treatment.
Ranibizumab Biosimilar Shows Reduced Efficacy vs Aflibercept in nAMD
April 3rd 2025The ranibizumab biosimilar Ongavia exhibited significantly less improvement in visual acuity and retinal thickness compared with aflibercept (Eylea) in treating neovascular age-related macular degeneration (nAMD), highlighting a potential trade-off between economic savings and clinical efficacy.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilars Gastroenterology Roundup: March 2025
April 1st 2025As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, market dynamics, and patient accessibility remain key hurdles to unlocking its full potential.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
FDA Approves Another Pair of Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for osteoporosis, bone metastases, and other bone-related conditions, amidst a flurry of similar approvals and legal settlements.